Cambridge Healthtech Institute’s 5th Annual

Oligonucleotide Discovery and Delivery

Optimizing Design, Delivery and Performance

March 17-18, 2020


CHI’s Oligonucleotide Discovery and Delivery conference reveals the latest strategies at the forefront of discovery, chemistry and delivery with in-depth sessions on new chemistries, novel delivery mechanisms and the most important preclinical and clinical advances. Leading oligonucleotide scientists deliver detailed case studies on antisense, RNA, aptamers and conjugates – helping you develop the next generation of targeted oligonucleotide therapeutics.


Coverage will include, but is not limited to:


  • Developments from early discovery through to late-stage clinical programs
  • Advances in the following areas, including but not limited to: the CNS, the liver, inhalation drugs, immuno- oncology and ocular diseases
  • Adoption and implementation of innovative technologies used in discovery and delivery
  • Examining the safety and toxicity of nucleic acid therapeutics
  • Strategic collaboration between big pharma and small biotechs


If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is September 9th 2020.


All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:

Gemma Smith

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+44) 7754-518-131


For partnering and sponsorship information, please contact:

Carolyn Cooke

Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5412



Oligonucleotide Discovery and Delivery